Micafungin

Generic Name: Micafungin

Brand Names: Mycamine

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₇₁N_₉O_₂₃S

CAS Number: 235114-32-6

Unique Ingredient Identifier: R10H71BSWG

Background: Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

Indication: Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.

Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Associated Conditions: Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis

Clinical Trials

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

Phase 3

Completed

Conditions: Fungemia
Fungal Infections

Interventions: Drug: micafungin (Mycamine)
Drug: itraconazole

First Posted Date: 2008-11-20

Last Posted Date: 2016-03-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 288

Registration Number: NCT00794703

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

Phase 3

Completed

Conditions: Candidiasis, Oral

Interventions: Drug: Fluconazole
Drug: Micafungin

First Posted Date: 2008-04-24

Last Posted Date: 2014-09-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 523

Registration Number: NCT00666185

Locations: 🇿🇦
2 Sites, Port Elizabeth, South Africa
🇵🇪
4 Sites, Lima, Peru
🇧🇷
8 Sites, Sao Paulo, Brazil

and more 2 locations

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

Phase 3

Completed

Conditions: Candidiasis, Oral

Interventions: Drug: micafungin
Drug: caspofungin

First Posted Date: 2008-04-24

Last Posted Date: 2014-08-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 454

Registration Number: NCT00665639

Locations: 🇧🇷
7 Sites, Sao Paulo, Brazil
🇧🇷
3 Sites, Belo Horizonte, Brazil
🇦🇷
5 Sites, Buenos Aires, Argentina

and more 2 locations

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Phase 1

Completed

Conditions: Oropharyngeal Candidiasis
Candidemia
Invasive Candidiasis
Esophageal Candidiasis

Interventions: Drug: Micafungin

First Posted Date: 2008-02-06

Last Posted Date: 2024-11-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 84

Registration Number: NCT00608335

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

and more 10 locations